According to these results, we speculate ICT could be used to treat the NSCLC patients with low infiltration of CD8+ T cells, which provided the basis for the sponsors to set inclusion/exclusion criteria in future trial design. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.